Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 27, 2016
50 pages — Published Sep 27, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Vifor Pharma AG (Vifor Pharma), a subsidiary of Galenica Ltd., is a specialty pharmaceutical company which discovers, develops, manufactures, and commercializes prescription and over-the-counter pharmaceutical products for the treatment of iron replacement therapy. The companys portfolio encompasses products for treatment of iron deficiency, a range of non-prescription products for the treatment of infectious diseases, and iron based phosphate binder for controlling serum phosphorus levels in patients with chronic kidney disease undergoing dialysis.

Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financial

  
Source:
Document ID
GDPH185425D
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Vifor Pharma AG, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201652
Vifor Pharma AG, Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201671
Vifor Pharma AG, Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201681
Vifor Pharma AG, Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 201692
Vifor Pharma AG, Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 2016112
Vifor Pharma AG, Pharmaceuticals &Healthcare, Deal Details1333
  Venture Financing131
    Relypsa Raises US$80 Million In Series C Financing132
    Relypsa Secures US$70 Million In Series B Financing Round152
    Relypsa Raises US$4 Million In Venture Financing171
  Partnerships181
    Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma181
    Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl191
    Probi Enters Into Co-Marketing Agreement With Vifor Pharma201
    Nycomed International Management Enters Into Distribution Agreement With Vifor Pharma For Intravenous Iron Products211
    Evotec Enters Into Co-Development Agreement With Vifor Pharma221
  Licensing Agreements231
    Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit231
    Vifor Pharma Enters into Licensing Agreement with ChemoCentryx for CCX168242
    Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject262
    Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron282
    Vifor Pharma Enters into Licensing Agreement with Bitop for Ectoin Allergy Eye Drops and Ectoin Allergy Nasal Sprays301
    Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin311
    Hikma Pharma Enters Into Licensing Agreement With Vifor Pharma For Ferinject322
    Kissei Pharma Enters Into Licensing Agreement With Vifor Pharma341
    Helsinn Enters Into Licensing Agreement With Vifor Pharma For Gelclair351
  Equity Offering361
    Relypsa Raises USD172 Million in Public Offering of Shares362
    Relypsa Completes Public Offering Of Shares For US$101.2 Million382
    Relypsa Completes IPO For US$86.7 Million402
  Acquisition421
    Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer422
    Relypsa May Sell Itself441
    Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach451
Vifor Pharma AG - Key Competitors461
Key Employees471
Locations And Subsidiaries482
  Head Office481
  Other Locations &Subsidiaries482
Appendix501
  Methodology501
  About GlobalData501
  Contact Us501
  Disclaimer501

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Vifor-Pharma-AG-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-6682>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Vifor-Pharma-AG-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-6682>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research